Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Director departure
Quarterly results
ARATANA THERAPEUTICS, INC. (PETX) Create: Alert

All | News | Filings
Date FiledTypeDescription
07/18/2019 8-K Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Sta...
Docs: "Amended and Restated Certificate of Incorporation of Aratana Therapeutics, Inc",
"Amended and Restated Bylaws of Aratana Therapeutics, Inc"
07/16/2019 8-K Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits
Docs: "Aratana Therapeutics' Stockholders Adopt Merger Agreement with Elanco Animal Health"
07/02/2019 8-K Other Events
06/07/2019 8-K Submission of Matters to a Vote of Security Holders
05/08/2019 8-K Quarterly results
Docs: "Aratana Therapeutics Reports First Quarter 2019 Financial Results Continued revenue growth across portfolio of marketed pet therapeutics"
04/26/2019 8-K Acquisition/merger/asset purchase announced
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of report : April 26, 2019 ARATANA THERAPEUTICS, INC. Delaware 001-35952 38-3826477 11400 Tomahawk Creek Parkway, Suite 340, Leawood, KS 66211 353-1000 N/A Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☒ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule 13e-...",
"Agreement and Plan of Merger, by and among Elanco Animal Health Incorporated, Elanco Athens Inc. and Aratana Therapeutics, Inc. (including the Form of Contingent Value Rights Agreement)",
"First Amendment, to the Amended and Restated Exclusive License, Development and Commercialization Agreement, by and between Aratana Therapeutics, Inc. and Pacira Pharmaceuticals, Inc",
"Aratana Therapeutics to be Acquired by Elanco Animal Health"
03/15/2019 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
03/12/2019 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "Aratana Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results"
02/05/2019 8-K Quarterly results
01/22/2019 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Letter Agreement, between the Company and Steven St. Peter, M.D",
"Amended and Restated Employment Agreement, between the Company and Craig Tooman"
01/04/2019 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
12/28/2018 8-K Termination of a Material Definitive Agreement
11/01/2018 8-K Quarterly results
Docs: "Aratana Therapeutics Reports Third Quarter 2018 Financial Results"
08/02/2018 8-K Quarterly results
Docs: "Aratana Therapeutics Reports Second Quarter 2018 Financial Results"
08/01/2018 8-K Submission of Matters to a Vote of Security Holders
07/09/2018 8-K Entry into a Material Definitive Agreement
06/01/2018 8-K Other Events
05/21/2018 8-K Resignation/termination of a director
Docs: "Cooperation Agreement, by and among Aratana Therapeutics, Inc., Engaged Capital, LLC and the other parties listed on Annex A thereto"
05/03/2018 8-K Quarterly results
Docs: "Aratana Therapeutics Reports First Quarter 2018 Financial Results"
04/05/2018 8-K Other Events, Financial Statements and Exhibits
03/13/2018 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "Aratana Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results"
01/11/2018 8-K Other Events
12/20/2017 8-K Other Events
12/18/2017 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
Docs: "Opinion of Latham & Watkins LLP",
"Sales Agreement, by and between Aratana Therapeutics, Inc. and Cowen and Company, LLC"
11/27/2017 8-K Other Events
11/13/2017 8-K Other Events
11/02/2017 8-K Quarterly results
Docs: "Aratana Therapeutics Reports Third Quarter 2017 Financial Results"
08/03/2017 8-K Quarterly results
06/22/2017 8-K Form 8-K - Current report
05/08/2017 8-K Form 8-K - Current report
05/04/2017 8-K Form 8-K - Current report
03/13/2017 8-K Form 8-K - Current report
02/06/2017 8-K Form 8-K - Current report
11/03/2016 8-K Form 8-K - Current report
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy